CancerNetwork Members: Login | Register
CancerNetwork SearchMedica Medline Drugs

Powered by SearchMedica

 
PUBLICATIONS
NEWS
PODCASTS
TOPICS
BLOGS
NURSES
PATIENTS
JOBS
CONFERENCES
CME
SUPPLEMENTS
 

Home » Integrative Oncology

ONCOLOGY. Vol. 25 No. 14
INTEGRATIVE ONCOLOGY 

Green Tea (Camellia sinensis)

Complementary Therapies, Herbs, and Other OTC Agents

By Guest Editor Barrie Cassileth, PhD1 | December 31, 2011
1Laurance S. Rockefeller Chair and Chief, Integrative Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York

ALSO KNOWN AS: Chinese tea, green tea extract, green tea polyphenols, epigallocatechin gallate (EGCG).

BACKGROUND: Green tea, derived from the leaves of Camellia sinensis, is consumed widely in Asia. Originally cultivated in East Asia, the plant is now grown in the Middle East and in some parts of Africa. Green tea has gained global popularity over the last few decades.

The leaves used to produce green tea are unfermented. They are steamed or heated immediately following harvest. This minimizes oxidation of the polyphenols, which are compounds that act as antioxidants and are thought to confer the health benefits attributed to green tea.

Green tea has been used in traditional medicine as a stimulant, as a diuretic, for wound healing, to promote digestion, and to improve heart health. More recently, green tea and its extracts have been used to prevent and treat hyperlipidemia, hypertension, atherosclerosis, and cancer.

Green tea is available as a dietary supplement in capsule form, as an extract, and in ointments for external application.

TAKE HOME POINTS
• Green tea, popular in China for over 4,000 years, enjoys a worldwide reputation for conferring a variety of health benefits.
• Evidence of the chemopreventive potential of green tea is limited to preclinical and epidemiologic studies.
• Green tea extract can interact with many prescription drugs. Because of its antioxidant effects, green tea extract may also affect chemotherapy and radiotherapy.

For additional information, visit the Memorial Sloan-Kettering Cancer Center Integrative Medicine Service website, “About Herbs,” at http://www.mskcc.org/AboutHerbs.

RESEARCH: The active constituent of green tea extract is EGCG, which accounts for 40% of its total polyphenol content. Regular consumption of green tea may reduce the risk of hypertension[1] and positively affect mood.[2] It also enhances glucose tolerance in healthy individuals[3] but did not improve insulin sensitivity or glycemic control in those with type 2 diabetes.[4] Green tea also may reduce mortality due to cardiovascular disease in both men and women.[5] Topical application of green tea extracts was shown to be effective against external genital and perianal warts.[6] A green tea extract, sinecatechin, used for genital warts, is an FDAapproved drug.

Several pre-clinical, case-control and prospective cohort studies show that green tea has chemopreventive properties.[7-9] However, a metaanalysis of epidemiologic studies failed to find that green tea prevents stomach cancer.[10] The FDA recently concluded that green tea is unlikely to reduce the risk of breast or prostate cancer.[11] Randomized clinical trials, currently underway, may help resolve the uncertainty surrounding the anticancer potential of green tea.

ADVERSE REACTIONS: Several cases of hepatitis have been associated with consumption of green tea.[12-14] A 40-year-old woman developed pruritic swelling and darkening of the lower lip following use of green tea for several years. Symptoms resolved after she discontinued consumption of green tea. [15] A 38-year-old woman developed thrombotic thrombocytopenic purpura following green tea supplementation for weight loss.[16]

Animal studies indicate that oral consumption of green tea extract while fasting can increase the risk of toxicity.[17]

HERB-DRUG INTERACTIONS: Anticoagulants/ antiplatelets: Theoretically, consumption of large amounts of green tea (0.5–1.0 gallon/day) may provide enough vitamin K to antagonize the effects of anticoagulants and antiplatelet agents, although this effect has not been reported in humans.[18]

Bortezomib (Velcade): EGCG and other polyphenols in green tea can inhibit the therapeutic effect of bortezomib(Drug information on bortezomib) and other boronic acid–based proteasome inhibitors.[19]

Tamoxifen: EGCG was shown to increase the oral bioavailability of tamoxifen(Drug information on tamoxifen).[20]

Verapamil: The bioavailability of verapamil(Drug information on verapamil) increased significantly in the presence of EGCG, an effect thought to be due to P-glycoprotein inhibition by EGCG.[21]

Irinotecan: A study found EGCG to inhibit the transport of irinotecan(Drug information on irinotecan) and its metabolite SN-38 into biliary elimination, resulting in prolongation of their half-life, which can increase toxicity.[22]

Cytochrome P450 3A4 substrates: Green tea extract inhibits CYP3A4 and can affect the intracellular concentration of drugs metabolized by this enzyme.[12]

UGT (uridine 5'-diphospho-glucuronosyltransferase) substrates: Green tea modulates UGT enzymes in vitro and can increase the side effects of drugs metabolized by them.

 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.





REFERENCES

1.Yang YC, et al. The protective effect of habitual tea consumption on hypertension. Arch Intern Med. 2004;164:1534-40.

2. Brown AL, Lane J, Coverly J, et al. Effects of dietary supplementation with the green tea polyphenol epigallocatechin-3-gallate on insulin resistance and associated metabolic risk factors: randomized controlled trial. Br J Nutr. 101:886-94.

3. Venables MC, Hulston CJ, Cox HR, Jeukendrup AE. Green tea extract ingestion, fat oxidation, and glucose tolerance in healthy humans. Am J Clin Nutr. 2008;87:778-84.

4. Mackenzie T, Leary L, Brooks WB. The effect of an extract of green and black tea on glucose control in adults with type 2 diabetes mellitus: double-blind randomized study. Metabolism. 2007;56:1340-4.

5. Kuriyama S, Shimazu T, Ohmori K, et al. Green tea consumption and mortality due to cardiovascular disease, cancer, and all causes in Japan: the Ohsaki study. JAMA. 2006;296:1255-65.

6. Stockfleth E, Beti H, Orasan R, et al. Topical polyphenon E in the treatment of external genital and perianal warts: a randomized controlled trial.Br J Dermatol. 2008;158:1329-38.

7. Pisters KM, Newman RA, Coldman B, et al. Phase I trial of oral green tea extract in adult patients with solid tumors. J Clin Oncol. 2001;19:1830-8.

8. Sun CL, Yuan JM, Lee MJ, et al. Urinary tea polyphenols in relation to gastric and esophageal cancers: a prospective study of men in Shanghai, China. Carcinogenesis 2002;23:1497-503.

9. Tsao AS, Liu D, Martin J, et al. Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions. Cancer Prev Res (Phila Pa). 2009;2:931-41.

10. Myung SK, Bae WK, Oh SM, et al. Green tea consumption and risk of stomach cancer: a meta-analysis of epidemiologic studies. Int J Cancer. 2009;124:670-7.

11. Letter from FDA. Green tea and cancer. Available from: http://www.fda.gov/Food/LabelingNutrition/LabelClaims/QualifiedHealthClaims/ucm073992.htm#gtea. Issued February 24, 2011. Accessed October 18, 2011.

12. Mazzanti G, Menniti-Ippolito F, Moro PA, et al. Hepatotoxicity from green tea: a review of the literature and two unpublished cases. Eur J Clin Pharmacol. 2009;65:331-41.

13. Vanstraelen S, Rahier J, Geubel AP. Jaundice as a misadventure of a green tea (Camellia sinensis) lover : a case report. Acta Gastroenterol Belg. 2008;71:409-12.

14. Verhelst X, Burvenich P, Van Sassenbroeck D, et al. Acute hepatitis after treatment for hair loss with oral green tea extracts (Camellia sinensis). Acta Gastroenterol Belg. 2009;72:262-4.

15. Lee JI, Cho BK, Ock SM, Park HJ. Pigmented contact cheilitis: from green tea? Contact Dermatitis. 2010;62:60-1.

16. Liatsos GD, Moulakakis A, Ketikoglou I, Klonari S. Possible green tea-induced thrombotic thrombocytopenic purpura. Am J Health Syst Pharm. 2010;67:531-4.

17. Wu KM. Green tea extract induced lethal toxicity in fasted but not in nonfasted dogs. Int J Toxicol. 2010;(1):19-20

18. Taylor JR, Wilt VM. Probable antagonism of warfarin by green tea. Ann Pharmacother 1999;33:426-8.

19. Goldin EB, Lam P, Kardosh A, et al. Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid based proteasome inhibitors. Blood. 2009;113:5927-37.

20. Shin SC, Choi JS. Effects of epigallocatechin gallate on the oral bioavailability and pharmacokinetics of tamoxifen and its main metabolite, 4-hydroxytamoxifen, in rats. Anticancer Drugs. 2009;20:584-8.

21. Chung JH, Choi DH, Choi JS. Effects of oral epigallocatechin gallate on the oral pharmacokinetics of verapamil in rats. Biopharm Drug Dispos. 2009;30:90-3.

22. Lin LC, Wang MN, Tsai TH. Food-drug interaction of (-)-epigallocatechin-3-gallate on the pharmacokinetics of irinotecan and the metabolite SN-38. Chem Biol Interact. 2008;174:177-82.

23. Mohamed ME, Frye RF. Effects of herbal supplements on drug glucuronidation. Review of clinical, animal, and in vitro studies. Planta Med. 2011;77:311-21.


 
RELATED CONTENT

Integrative Medicine: Not Just Garnish
ONCOLOGY Nurse Edition,  May 9, 2012
Green Tea (Camellia sinensis)
ONCOLOGY,  December 31, 2011
Flaxseed (Linum usitatissimum)
ONCOLOGY,  November 15, 2011
Coenzyme Q10
ONCOLOGY Nurse Edition,  October 19, 2011
Essiac
ONCOLOGY,  October 11, 2011
 
TOPIC INDEX

  • Bone Metastases
  • Breast Cancer
  • CML
  • Colorectal Cancer
  • End-of-Life
  • GI Cancers
  • GIST
  • GU Cancers
  • Gynecologic Cancers
  • Head & Neck Cancer
  • Hematology
  • Leukemia
  • Lung Cancer
  • Lymphoma
  • Melanoma
  • Nausea & Vomiting
  • Palliative Care
  • Pancreatic Cancer
  • Practice Management
  • Practice & Policy
  • Prostate Cancer
  • RCC
  • Skin Cancer
  • Triple-Negative Breast


More Topics 


 
   SEARCH MEDICA RX
   Browse drugs by name:
A B C D E F G H I J
K L M N O P Q R S T
U V W X Y Z All      
   Search for drugs:
Search

 

 
FROM PHYSICIANS PRACTICE
Physician Performance Goals Are Great, But Balance Is More Realistic
Jennifer Frank, MD,  May 15, 2012
Performance measurements for physicians are well-intentioned and get me to rethink how I practice. But in the end I won't make the goals, so I'll have to go with balance over perfection.
Designing the Perfect Business Card for Your Medical Practice
C. Noel Henley, MD,  May 11, 2012
Does your business card say anything substantive about the valuable work you do in your practice? Here’s how to re-design your next business card for maximum impact and engagement.
Registered Nurses an Ideal Fit for Primary Care Practices
Audrey "Christie" McLaughlin, RN,  May 10, 2012
Here are four good reasons to hire a registered nurse for your primary care practice …maybe even instead of a medical assistant.
The Five Biggest Medical Practice Marketing Mistakes
James Doulgeris,  May 10, 2012
There are best practices to marketing your practice, but often, success is more about knowing what not to do. Here are the five most common pitfalls …and how to avoid them.
Can You Practice Medicine and Manage Your Practice?
Rosemarie Nelson,  May 9, 2012
Whether you practice alone, or in a group, if you're trying to see patients in this pay-for-volume environment and also run the business of your practice, you may be missing out on important opportunities.
 
MOST POPULAR
  • Most Popular
  • Most Emailed
  • Most Recent
  • A 54-Year-Old Woman Notes the Abundant Development of Nonpigmented Hair on Her Ears and Nose
  • Head and Neck Tumors
  • A 45-Year-Old Woman Presents With Severe Back Pain; Examination Reveals Nephrolithiasis
  • A 58-Year-Old Man Presents With Abdominal Pain and Jaundice
  • Treatment of Castration-Resistant Prostate Cancer: Current Options and Novel Therapies
  • Study Highlights Communication "Breakdowns" in Cancer Care
  • Pazopanib (Votrient) Gets FDA Approval for Advanced Soft-Tissue Sarcoma
  • Brain Tumor Vaccine Shows Promise
  • Physical Activity in Cancer Survivors Associated With Better Health Outcomes
  • Treatment of Castration-Resistant Prostate Cancer: Current Options and Novel Therapies
  • New Way to Target B-Cell Lymphomas
  • How I Survived Chemotherapy
  • Lenalidomide Maintenance for Multiple Myeloma Improves Survival
  • Identifying Appropriate Patient Groups and Drug Targets in DLBCL
  • Diffuse Large B-Cell Lymphoma: Current Treatment Approaches
Click here to subscribe to our newsletter
 
COMMENTS
  • Most Commented
  • Most Recent
  • Treatment of Castration-Resistant Prostate Cancer: Current Options and Novel Therapies
  • Online Support Tool Reduces Depression, Ups QOL in Cancer Patients
  • Physical Activity in Cancer Survivors Associated With Better Health Outcomes
  • Physical Activity in Cancer Survivors Associated With Better Health Outcomes
  • Online Support Tool Reduces Depression, Ups QOL in Cancer Patients
  • Treatment of Castration-Resistant Prostate Cancer: Current Options and Novel Therapies
  • “I’m Not Going to Treat Your Cancer”
  • The Hateful Patient
Click here to subscribe to our newsletter
 
JOB LISTINGS

Post a job

Powered by SearchMedica Jobs


 
SearchMedica Search Result

Find peer-reviewed literature and websites for practicing medical professionals

CME on Integrative Oncology
Evidence on Integrative Oncology
Guidelines on Integrative Oncology
Patient Education on Integrative Oncology
Clinical Trials on Integrative Oncology
Practical Articles on Integrative Oncology
Research and Reviews on Integrative Oncology
All "Integrative Oncology" results


CancerNetwork on Facebook

 

CancerNetwork | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2012 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy